Financing High-Cost Gene Therapy Under Clinical Uncertainty: Assessing Budget Impact of Reimbursement Models for Hemgenix® in Hemophilia B in Sweden
Applied Health Economics and Health Policy · 26.10.2026
DOI: 10.1007/s40258-026-01077-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Health Economics and Health Policy, online erschienen am 26.10.2026. Verfasst von Shalini Padhy und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health and Community Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aim
Advanced therapy medicinal products, a European Union regulatory category encompassing gene-, cell-, and tissue-based medicines, challenge conventional reimbursement frameworks, particularly when a single administration entails high upfront costs and long-term effectiveness uncertainty. This study assessed the treatment-cost budget impact under three reimbursement models for etranacogene dezaparvovec (Hemgenix^®) in hemophilia B within the high-income, decentralized, tax-financed healthcare system of Sweden.
Methods
Using a decision-support framework, an outcome-based annuity model was identified as a relevant reimbursement strategy for Hemgenix^®. A cohort Markov model simulated per-patient treatment costs for payers for Hemgenix^® and the comparator factor IX prophylaxis over 5, 10, and 15 years for a hypothetical cohort of adults with hemophilia B. Three reimbursement strategies—full upfront, 30% reduced upfront, and outcome-based annuity reimbursement—were compared with costs for factor IX prophylaxis under three scenarios: short-term trial outcomes, a full response, and partial response (10% annual failure rate). One-way sensitivity analyses examined varying treatment durability, cost of Hemgenix^® and factor IX prophylaxis, mortality rates, and extended time horizon.
Results
Hemgenix^® was more expensive than standard prophylaxis in the first 10 years under all scenarios and reimbursement strategies in Sweden. However, at 15 years, the 30% reduced upfront model and outcome-based annuity model incur lower treatment costs than prophylaxis in selected scenarios. Under sustained full treatment response, the reduced upfront reimbursement model showed the lowest treatment costs, while the outcome-based annuity model resulted in lower costs under partial and diminishing treatment effectiveness.
Conclusion
In this Swedish, budget-impact analysis, the treatment cost of Hemgenix^® depended strongly on assumptions about long-term durability and reimbursement design. The study shows outcome-based annuity reimbursements reduce payers’ treatment-cost exposure under long-term uncertainty, whereas upfront reimbursement minimized the cost of Hemgenix^® treatment only with sustained response. However, this cost advantage under partial response was not maintained after applying 3% annual discounting.
Autor:innen und Institutionen
- School of Public Health and Community Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- HEPER (Health Economics, Policy and Evaluation), Institute of Medicine, School of Public Health and Community Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. pia.johansson@gu.se.
Zitieren
APA
Padhy, S., & Johansson, P. (2026). Financing High-Cost Gene Therapy Under Clinical Uncertainty: Assessing Budget Impact of Reimbursement Models for Hemgenix® in Hemophilia B in Sweden. Applied Health Economics and Health Policy. https://doi.org/10.1007/s40258-026-01077-9
Vancouver
Padhy S, Johansson P. Financing High-Cost Gene Therapy Under Clinical Uncertainty: Assessing Budget Impact of Reimbursement Models for Hemgenix® in Hemophilia B in Sweden. Applied Health Economics and Health Policy. 2026. doi:10.1007/s40258-026-01077-9
BibTeX
@article{Padhy2026,
author = {Padhy, Shalini and Johansson, Pia},
title = {Financing High-Cost Gene Therapy Under Clinical Uncertainty: Assessing Budget Impact of Reimbursement Models for Hemgenix® in Hemophilia B in Sweden},
journal = {Applied Health Economics and Health Policy},
year = {2026},
doi = {10.1007/s40258-026-01077-9}
}
EUVIMED